GlassScriptPhysician profile
Alyce G Abraham
NPI 1538204805
$6,165.16
in general payments reported to CMS, 2019-2025
36 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,117 · 2022: $1,169 · 2023: $1,038 · 2024: $1,747 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,878.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $907.76 | 2021-2025 | Botox |
| Axonics, INC. | $683.34 | 2021-2024 | Axonics |
| Bayer Healthcare Pharmaceuticals INC. | $491.57 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $337.46 | 2023-2025 | Gemtesa, Myfembree |
| Astrazeneca Pharmaceuticals LP | $336.39 | 2022-2024 | Fasenra |
| Abiomed | $243.45 | 2022-2025 | |
| Astellas Pharma US INC | $234.63 | 2021-2024 | Myrbetriq, Veozah |
| Ultragenyx Pharmaceutical INC. | $207.90 | 2022-2023 | Crysvita |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $197.46 | 2023-2024 | |
| Agile Therapeutics, INC. | $184.48 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.32 | 2022-2023 | |
| Abbott Laboratories | $175.91 | 2024 | Proclaim |
| Hologic Sales and Service, LLC | $148.72 | 2025 | Aptima |
| Angiodynamics, INC. | $129.17 | 2023 | Auryon Laser System 100-120 Vac |
| Evoke Pharma, INC. | $124.99 | 2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $124.99 | 2024 | Yupelri |
| Mayne Pharma Commercial LLC | $124.74 | 2023 | |
| Genzyme Corporation | $120.58 | 2024 | |
| Axsome Therapeutics, INC. | $119.70 | 2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $117.02 | 2021 | |
| Neurelis, INC. | $108.61 | 2024 | Valtoco |
| Exact Sciences Corporation | $105.30 | 2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.25 | 2022 | |
| Corcept Therapeutics | $100.00 | 2024 | Korlym |
| Evofem Biosciences, INC. | $100.00 | 2021 | |
| Gilead Sciences, INC. | $92.99 | 2021 | |
| Medtronic, INC. | $85.42 | 2025 | Interstim |
| Pfizer INC. | $64.44 | 2021-2022 | |
| Rochester Medical Corporation | $57.62 | 2021 | |
| Abc Home Medical Supply, INC. | $31.21 | 2025 | |
| 180 Medical, INC. | $24.29 | 2024 | |
| C. R. Bard, INC. & Subsidiaries | $23.77 | 2025 | Bard Urinary Drainage Bag |
| Urovant Sciences INC | $21.99 | 2022 | |
| Boston Scientific Corporation | $21.66 | 2024 | Upsylon |
| Laborie Medical Technologies Corp. | $20.67 | 2022 | |
| Coloplast Corp | $20.36 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyce Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.